REALM THERAPEUTICS PLC ('PuriCore' or the 'Company')
Director Dealing
Name | Date purchased | Number of Shares purchased | Purchase price of Shares | Shareholding following the purchase | % of issued share capital |
Daniel Hegglin Non-Executive Director | 13 October 2015 | 500,000 | 18p | 5,909,091 | 11.79% |
-Ends-
Enquiries:
PuriCore plc | +44 (0) 20 3727 1000 | ||
Alex Martin, Chief Executive Officer Marella Thorell, Chief Financial Officer and Chief Operating Officer | |||
FTI Consulting | +44 (0) 20 3727 1000 | ||
Simon Conway / Mo Noonan / Victoria Foster Mitchell | |||
N+1 Singer (Nominated Adviser & Broker) | +44 (0) 20 7496 3000 | ||
Aubrey Powell / Jen Boorer / Thomas Smale | |||
About PuriCore
PuriCore is an international company, focused on developing and commercialising products based on its proprietary hypochlorous acid platform technology, to address significant unmet needs in human health. PuriCore's products are currently used in two broad market segments: Supermarket Retail and Health Sciences. PuriCore's products do not cause harm to human or animal life or to the environment. The Group is headquartered in Malvern, Pennsylvania.
In the Supermarket Retail segment, PuriCore's products are used by customers to enhance quality and freshness of produce and floral products. Product offerings include the Sterilox® Fresh Systems (capital equipment) that are installed at customer locations and allow for generation of the solution as needed at the store. ProduceFresh® is the Company's concentrate bottled version of the solution for produce application. Customers use FloraFresh®, also sold as a concentrate in bottled form, to improve the freshness of cut flowers. ProduceFresh and FloraFresh are diluted for use by customers through the Company's concentrate delivery systems.
In Health Sciences, PuriCore offers a range of products to manage a variety of skin and wound conditions under a medical device registration.
|
distributed by
|
